Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.9552W HIGH $12.43
Volume
10.49 M
Value Traded
45.10 M
Short % Float
31.27%
-3.65%Week
+22.95%1 Month
+20.56%3 Month
+36.13%6 Month
-58.87%5 Year
-80.49%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
10.50 B
EPS (TTM)
-0.94
P/E Ratio
-
Ent. Value
10.15 B
Total Shares
1.06 B
Float Shares
400.99 M
Insiders
62.17%
Institutions
19.30%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
IBRX Catalyst Timeline
Dated clinical, regulatory and corporate events for ImmunityBio, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for ImmunityBio, Inc.
251Total events
17Upcoming
75Tier-1 (high impact)
2019 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Other Regulator MilestoneANKTIVAApprovedEx-US Regulatory
UAE grants marketing authorization for ANKTIVA in NMIBC and NSCLC
BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) and metastatic non-small cell lung cancer (NSCLC)source ↗
▲Other Regulator MilestoneANKTIVAApprovedEx-US Regulatory
UAE Marketing Authorization for ANKTIVA in BCG-unresponsive NMIBC (CIS and papillary disease)
BCG-unresponsive non-muscle invasive bladder cancer (CIS and papillary disease)source ↗
▲FDA ApprovalANKTIVAApprovedFDA Decision
UAE Emirates Drug Establishment granted broadest marketing authorization for ANKTIVA across BCG-unresponsive NMIBC and metastatic NSCLC
BCG-unresponsive NMIBC for CIS and papillary disease and metastatic NSCLCsource ↗
◆Poster PresentationANKTIVAApprovedPresentation
Poster presentation: QUILT-3.055 Phase 3 trial of ANKTIVA + checkpoint inhibitor in advanced NSCLC
non-small cell lung cancer (NSCLC)source ↗
▲Oral PresentationANKTIVAApprovedPresentation
Health economic analysis presentation at ISPOR 2026
BCG-unresponsive NMIBC CISsource ↗
●Oral PresentationPresentation
Patient survey data presented at ISPOR 2026 showing UK adults with NMIBC favor bladder preservation
non-muscle invasive bladder cancer (NMIBC)source ↗
▲sBLA SubmissionANKTIVAApprovedRegulatory Filing
FDA acceptance of supplemental BLA for ANKTIVA plus BCG
BCG-unresponsive non-muscle invasive bladder cancer with papillary diseasesource ↗
▲Oral Presentationnogapendekin alfa inbakicept-pmlnPresentation
Presentation of ITC analyses comparing NAI+BCG vs nadofaragene and TAR-200 at AUA 2026
BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situsource ↗
▲Patent GrantedANKTIVAApprovedIP / Competition
U.S. patents covering combination of ANKTIVA with BCG for cancer treatment, terms through 2035
cancersource ↗
▲Partnership / LicenseCorporate
Exclusive U.S. Development and Supply Agreement with Japan BCG Laboratory for Tokyo strain of BCG
●Oral PresentationPresentation
Dr. Patrick Soon-Shiong presentation at AUA Annual Meeting: 'The Role of IL-15 in the Urological Setting'
Urological oncology (bladder and prostate cancer)source ↗
◆Oral PresentationPresentation
Update on BCG Naïve Registrational Trial at AUA Annual Meeting
BCG Naïve Non-Muscle Invasive Bladder Cancersource ↗
▲Product LaunchANKTIVAApprovedPost-Market
ANKTIVA commercially available in Saudi Arabia
bladder cancer; lung cancersource ↗
▲Enrollment CompleteANKTIVAApprovedTrial
Pivotal BCG-naïve CIS trial fully enrolled, IDMC confirms no additional enrollment required
BCG-naïve CIS (bladder cancer)source ↗
●BLA SubmissionANKTIVAApprovedRegulatory Filing
Supplemental BLA for BCG-unresponsive NMIBC with papillary-only disease filed
BCG-unresponsive NMIBC with papillary-only diseasesource ↗
●Information RequestANKTIVAApprovedRegulatory Filing
ImmunityBio submitted response to FDA OPDP
BCG-unresponsive non-muscle invasive bladder cancersource ↗
◆Enrollment CompleteANKTIVAApprovedTrial
Enrollment completion expected by Q2 2026 for QUILT-2.005 trial
BCG-naïve non-muscle invasive bladder cancersource ↗
▲Debt Royalty FinancingCorporate
Secured $75 million non-dilutive financing under Royalty Interest Purchase Agreement with Oberland Capital
▼Equity OfferingCorporate
Nant Capital converted $25 million principal amount into 4.6 million shares of common stock
▲FDA ApprovalANKTIVAApprovedFDA Decision
ANKTIVA approved or authorized in five regulatory jurisdictions representing approximately 34 countries
BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS)source ↗
▲Quarterly UpdateANKTIVAApprovedCorporate
Q1 2026 net product revenue of $44.2 million, up 168% YoY
▲Other Regulator MilestoneANKTIVAApprovedEx-US Regulatory
Regulatory approval in Macau SAR, China for ANKTIVA
BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) ± papillary tumorssource ↗
▲Oral PresentationANKTIVAApprovedPresentation
NCCN guidelines updated to include ANKTIVA plus BCG for papillary-only NMIBC
BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary-only diseasesource ↗
▼Warning Letter IssuedANKTIVAApprovedCMC / Inspection
FDA Warning Letter regarding false or misleading promotional claims for ANKTIVA
BCG-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situsource ↗
▼Information RequestANKTIVAApprovedRegulatory Filing
FDA OPDP letter regarding promotional materials
BCG-unresponsive non-muscle invasive bladder cancersource ↗
▲Manufacturing MilestoneCMC / Inspection
Successful completion of NK2022 and NK2023 manufacturing engineering programs
▲Trial CompletionM-CENKTrial
Phase 1 trial QUILT-3.076 combining M-ceNK with ANKTIVA completed
relapsed or refractory solid tumorssource ↗
●sBLA SubmissionANKTIVAApprovedRegulatory Filing
Resubmission of sBLA for ANKTIVA plus BCG in BCG-unresponsive NMIBC with papillary disease
BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary tumorssource ↗
▲Interim AnalysisANKTIVAApprovedTrial
IDMC interim analysis confirms adequate statistical power
BCG-naïve non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS)source ↗
◆FDA Feedback ReceivedANKTIVAApprovedFDA Meeting
FDA requested additional data in January 2026; company submitted in February 2026; FDA provided feedback in March 2026 requesting updated efficacy data
BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary tumorssource ↗
●Timing GuidancerBCGPresentation
Planned submission of rBCG regulatory package to SFDA
bladder cancer (BCG shortage)source ↗
▲Product LaunchANKTIVAApprovedPost-Market
Commercial launch in Saudi Arabia for ANKTIVA in NSCLC
metastatic NSCLCsource ↗
▲Enrollment CompleteANKTIVAApprovedTrial
Enrollment completed in Phase 2 trial of ANKTIVA plus BCG vs BCG alone in BCG-naïve NMIBC CIS
BCG-naïve non-muscle invasive bladder cancer carcinoma in situsource ↗
▲Interim AnalysisANKTIVAApprovedTrial
Interim analysis requested by FDA showed statistically significant improvement in duration of complete response for ANKTIVA plus BCG vs BCG alone
BCG-naïve non-muscle invasive bladder cancer carcinoma in situsource ↗
▲Other Regulator MilestoneANKTIVAApprovedEx-US Regulatory
Global regulatory approvals in 33 countries across 4 jurisdictions for ANKTIVA in NMIBC
BCG-unresponsive NMIBC CISsource ↗
▲Partnership / LicenseANKTIVAApprovedCorporate
Partnership with Biopharma and Cigalah Healthcare to launch ANKTIVA in Saudi Arabia and MENA region
BCG-unresponsive non-muscle invasive bladder cancer; metastatic non-small cell lung cancersource ↗
◆sNDA SubmissionANKTIVAApprovedRegulatory Filing
Submission of additional information to FDA for sBLA resubmission
BCG-unresponsive NMIBC with papillary tumorssource ↗
▲Full ResultsANKTIVAApprovedClinical Data
QUILT-3.032 results supporting EC authorization
BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situsource ↗
▲Other Regulator MilestoneANKTIVAApprovedEx-US Regulatory
Authorization in 33 countries across four regulatory jurisdictions
BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situsource ↗
▲Other Regulator MilestonerBCGEx-US Regulatory
SFDA encouraged submission of regulatory package for rBCG
bladder cancer (BCG shortage)source ↗
▲Other Regulator MilestoneANKTIVAApprovedEx-US Regulatory
Initiated discussions with SFDA for expansion of ANKTIVA plus CPI into additional tumor types
multiple tumor types (CPI relapsed)source ↗
▲Full ResultsANKTIVAApprovedClinical Data
QUILT-3.055 Phase 2b basket trial data across multiple tumor types
multiple tumor types (CPI relapsed)source ↗
▲EU ApprovalANKTIVAApprovedEx-US Regulatory
European Commission grants conditional marketing authorization for ANKTIVA plus BCG
BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situsource ↗
▲Trial InitiationResQ215BTrial
Launch of Phase 2 trial evaluating CD19 t-haNK + ANKTIVA + rituximab
indolent B-cell non-Hodgkin lymphoma (iNHL), including Waldenström's Macroglobulinemiasource ↗
▲Topline ReadoutTokyo-172Clinical Data
Positive Phase III readout of SWOG S1602 demonstrating non-inferiority of Tokyo strain BCG vs TICE BCG
BCG-naive high-grade non-muscle invasive bladder cancer (NMIBC)source ↗
Past FDA Catalysts and PDUFA Decisions
How IBRX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-05-02 | ANKTIVA | BLA Submission crl | BLA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
B63 / 100
Pipeline Score
$5.1B
Pipeline Value
$688M
Commercial Value
Overvalued
Valuation Signal
19
Drugs Scored
0.5x
rNPV / MCap
Top 5%
Mid Cap(rank 34 of 658)
Percentile Rank
ImmunityBio, Inc. holds a solid B-grade pipeline (63/100), with $6.0B risk-adjusted pipeline value, led by Nogapendekin alfa inbakicept in NSCLC Stage IV (Phase 3).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $165.8M x 4.2 = $688M
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| ANKTIVA | $165M | $56M | +194% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Nogapendekin alfa inbakicept Small moleculeNCT06745908 | NSCLC Stage IV | Phase 3 | RECRUITING | 507 | Jan 1, 2029 |
Clinical Trial Results
Readouts, endpoints and source filings for every IBRX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Tokyo-172 BCG | high-grade non-muscle invasive bladder cancer (NMIBC) | Phase 3 | 2026-05-16 | hazard ratio: 0.82; confidence interval: 95.8% CI 0.63-1.08Read More | ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States Positive Phase III readout of National Cancer Institute sponsored SWOG S1602 ranRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Simon Barry J.Director | Sell | -25,000 2,777,788 held | $10.75 | 10/05/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in IBRX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| GREAT POINT PARTNERS LLC | 5 % (-5.7 %) | 26.27 M | 3.00 M |
IBRX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-06 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How IBRX ranks across every disease it competes in
Competitive Position is a premium feature
See how IBRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialIBRX News
IBRX▲ +1.4%today
ImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium
ImmunityBio, Inc. has announced that Dr. Patrick Soon-Shiong will participate in a virtual fireside chat at the Piper Sandler Virtual Oncology Symposium scheduled for October 15-16, 2026. This event aims to focus on advancements in oncology and immunotherapy. Dr. Soon-Shiong's role emphasizes the company's commitment to leadership in the field.
Read more →IBRXImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman
ImmunityBio, Inc. has appointed Dr. Jim Yong Kim as Vice Chairman, a newly created role. Dr. Kim will focus on enhancing the company's global relationships and will report to Executive Chairman Dr. Patrick Soon-Shiong. This strategic move aims to leverage Dr. Kim's extensive experience in global health.
Read more →IBRXImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million
ImmunityBio, Inc. reported a record net product revenue of $50.7 million for Q2 2026, marking a 92% increase compared to the previous year and a 15% rise from the first quarter of 2026. The company also made significant progress in its immunotherapy pipeline, achieving its eighth consecutive quarter of growth. Overall, the financial results reflect strong operational performance.
Read more →IBRX▲ +9.1%on this newsshared move
ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer
ImmunityBio has received marketing authorization from the Emirates Drug Establishment for its product ANKTIVA across two cancer indications. The approval allows for the use of ANKTIVA in combination with BCG for treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) and metastatic non-small cell lung cancer (NSCLC). This marks a significant milestone for the company in expanding its market presence in the UAE.
Read more →IBRXImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026
ImmunityBio presented new clinical and comparative data related to lung and bladder cancer at ASCO 2026. The details of the findings were not disclosed in the provided text. The presentation aimed to showcase advancements in treatment options for these cancers. Further insights into the data are anticipated from the conference.
Read more →IBRX▼ -6.7%on this news
ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS
ImmunityBio presented a health economic analysis at ISPOR 2026, highlighting that ANKTIVA® combined with BCG offers a lower cost per sustained complete response compared to TAR-200 for patients with BCG-unresponsive NMIBC CIS. This analysis may influence treatment decisions in the management of bladder cancer.
Read more →IBRX▼ -6.7%on this news
ImmunityBio Highlights Patient Survey Data at ISPOR 2026 Showing Majority of UK Adults Living with NMIBC Favor Bladder Preservation
ImmunityBio presented patient survey data at ISPOR 2026, revealing that most UK adults living with non-muscle invasive bladder cancer (NMIBC) prefer bladder preservation strategies. This finding underscores the importance of patient preferences in treatment decisions. The data reflects a shift towards more patient-centered approaches in managing NMIBC.
Read more →IBRXImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027
ImmunityBio has announced that the FDA has accepted its supplemental Biologics License Application (BLA) for ANKTIVA® in combination with BCG for the treatment of BCG-unresponsive non-muscle invasive bladder cancer with papillary disease. The FDA has set a Prescription Drug User Fee Act (PDUFA) date for January 6, 2027, marking a key regulatory milestone for the company.
Read more →IBRXImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR-200 at AUA 2026
ImmunityBio presented data comparing the effectiveness of NAI + BCG against Nadofaragene and TAR-200 at AUA 2026. The results focused on complete response rates, but specific details about the findings were not disclosed in the article. The presentation highlights ongoing research in bladder cancer therapies.
Read more →IBRXImmunityBio Announces Comprehensive U.S. Patents Covering Combination of ANKTIVA with BCG for Cancer Treatment, with Terms Through 2035
ImmunityBio has announced the granting of comprehensive U.S. patents that cover the combination of its product ANKTIVA with BCG for cancer treatment. This patent protection is set to last until 2035, potentially providing a significant competitive advantage in the oncology market. The announcement highlights ImmunityBio's commitment to advancing cancer therapies.
Read more →IBRXImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States
ImmunityBio has entered into an exclusive U.S. Development and Supply Agreement with Japan BCG Laboratory for the Tokyo strain of BCG, enhancing BCG availability in the United States. This agreement follows positive Phase III results demonstrating the non-inferiority of Tokyo-172 compared to standard treatments. ImmunityBio plans to pursue FDA approval for the Tokyo strain, while continuing its partnership with Serum Institute of India for additional supply options. This development addresses long-standing BCG shortages faced by urologists and their patients in the U.S.
Read more →IBRX▼ -7.4%on this news
ImmunityBio Reports Record Q1 2026 Results: Net Product Revenue Increased Nearly 2.7x Year-Over-Year to $44 Million in Q1 2026 Expanding on the 2025 Full Year 700% Year-Over-Year Revenue Growth; Cash and Marketable Securities Total $381 Million
ImmunityBio reported impressive financial results for Q1 2026, with net product revenue reaching approximately $44.2 million, marking a 168% increase compared to Q1 2025. This growth reflects a consistent upward trend since the commercial launch of ANKTIVA. The company also reported a robust cash position of $381 million.
Read more →IBRXImmunityBio to Present New Comparative Data, Scientific Advances in Non-Muscle Invasive Bladder Cancer CIS and an Update on BCG Naïve Registrational Trial at American Urological Association Annual Meeting
ImmunityBio is set to present new comparative data and scientific advancements related to non-muscle invasive bladder cancer at the upcoming American Urological Association Annual Meeting. The presentation will also include an update on their BCG Naïve Registrational Trial. This event is expected to highlight the company's contributions to bladder cancer research.
Read more →IBRXIBRX Lawsuit Alleges Chairman Allegedly Overstated Drug Capabilities - ImmunityBio Investors Face Losses Following Chairman Allegedly Overstated Drug Capabilities: SueWallSt
A class action lawsuit has been filed against ImmunityBio, Inc. (IBRX) alleging that the company made false and misleading statements regarding its drug ANKTIVA. The lawsuit follows a significant stock decline after an FDA Warning Letter indicated that the company's promotional claims were misleading. Investors who purchased shares during the specified period may be eligible for compensation.
Read more →IBRXImmunityBio Announces ANKTIVA® Is Now Available in Saudi Arabia for Bladder and Lung Cancer Patients; Market Entry Achieved Within Two Months of MENA Partnership
ImmunityBio has announced the commercial availability of ANKTIVA® in Saudi Arabia for bladder and lung cancer patients. The entry into the market was accomplished within just two months following a partnership in the MENA region. The drug will be used in combination with BCG for treating specific cancer indications.
Read more →IBRXImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Million in Q1 2026 and $381 Million in Cash and Marketable Securities
ImmunityBio reported a significant increase in net product revenue for Q1 2026, reaching approximately $44.2 million, a 168% rise from Q1 2025. The company has seen consistent revenue growth since the launch of ANKTIVA, which is now approved in 34 countries. With $380.9 million in cash and marketable securities, ImmunityBio is focused on expanding its market presence and advancing its clinical pipeline.
Read more →IBRX▲ +7.2%on this newsshared move
ImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Million in Q1 2026 and $381 Million in Cash and Marketable Securities
ImmunityBio, Inc. reported a remarkable increase in net product revenue for Q1 2026, reaching approximately $44.2 million, which is a 168% growth compared to Q1 2025. This growth marks a continuous upward trend since the commercial launch of their product ANKTIVA. The company also reported having $381 million in cash and marketable securities.
Read more →IBRXImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance
ImmunityBio, Inc. has responded to concerns raised by the FDA regarding its advertising practices, specifically related to a podcast and an unbroadcast television advertisement. The company has committed to enhancing its compliance processes and ensuring that all promotional communications for its therapy ANKTIVA adhere to FDA regulations. ImmunityBio has implemented corrective actions including the removal of problematic content and training for executives. The company aims to maintain clarity in its communications regarding investigational drugs and approved therapies.
Read more →IBRX▲ +15.2%on this newsshared move
ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion and Advancement of Broader Immunotherapy Pipeline
ImmunityBio has successfully secured $100 million in financing, which includes $75 million in non-dilutive funding. This financing is intended to support the company's global expansion and further advancement of its immunotherapy pipeline following recent regulatory approvals. The company aims to enhance its commercial efforts, particularly with the immunotherapy drug ANKTIVA, which has received approval in 34 countries. These developments reflect ImmunityBio's increasing capacity to scale operations and develop next-generation therapies.
Read more →About ImmunityBio, Inc.
Headquarters3530 JOHN HOPKINS COURT, SAN DIEGO, CA, 92121
BIOPHARMAWATCH ELITE PLUS
Trade the next IBRX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime